NeuroPace, Inc. (NPCE)
Automate Your Wheel Strategy on NPCE
With Tiblio's Option Bot, you can configure your own wheel strategy including NPCE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NPCE
- Rev/Share 2.678
- Book/Share 0.7709
- PB 17.0058
- Debt/Equity 3.0142
- CurrentRatio 6.628
- ROIC -0.1937
- MktCap 429988322.0
- FreeCF/Share -0.5751
- PFCF -23.7497
- PE -22.6567
- Debt/Assets 0.6638
- DivYield 0
- ROE -1.4015
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | NPCE | H.C. Wainwright | -- | Buy | -- | $18 | May 28, 2025 |
| Initiation | NPCE | UBS | -- | Buy | -- | $17 | Jan. 21, 2025 |
News
NPCE ALERT: Ongoing Investigation Into NeuroPace, Inc. - Contact Levi & Korsinsky
Published: May 30, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of NeuroPace, Inc. ("NeuroPace, Inc.") (NASDAQ:NPCE) concerning possible violations of federal securities laws. NeuroPace issued a press release on May 27, 2025, "announc[ing] the preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for treatment of individuals with drug-resistant idiopathic generalized epilepsy (IGE).
Read More
Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE) Over Possible Securities Fraud
Published: May 29, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of NeuroPace, Inc. ("NeuroPace, Inc.") (NASDAQ:NPCE) concerning possible violations of federal securities laws. NeuroPace issued a press release on May 27, 2025, "announcing the preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for treatment of individuals with drug-resistant idiopathic generalized epilepsy (IGE).
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages NeuroPace, Inc. (NPCE) Investors to Inquire about Securities Investigation
Published: May 29, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NeuroPace, Inc. ("NeuroPace" or "the Company") (NASDAQ:NPCE). Investors who purchased NeuroPace securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NPCE.
Read More
NPCE ACTIVE INVESTIGATION: Lost Money on NeuroPace, Inc.? Contact Levi & Korsinsky Now
Published: May 29, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of NeuroPace, Inc. ("NeuroPace, Inc.") (NASDAQ:NPCE) concerning possible violations of federal securities laws. NeuroPace issued a press release on May 27, 2025, "announc[ing] the preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for treatment of individuals with drug-resistant idiopathic generalized epilepsy (IGE).
Read More
NPCE Stock Tumbles Despite Positive One-Year Data From NAUTILUS Trial
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Neutral
NeuroPace reports promising one-year results from its NAUTILUS trial, showcasing the RNS System's effectiveness in treating idiopathic generalized epilepsy with sustained seizure reduction.
Read More
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Five high-flying medical instrument stocks are: DXCM, IDXX, NPCE, CLPT, FMS.
Read More
Recent Price Trend in NeuroPace (NPCE) is Your Friend, Here's Why
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
If you are looking for stocks that are well positioned to maintain their recent uptrend, NeuroPace (NPCE) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Read More
NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting
Published: April 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
MOUNTAIN VIEW, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, will be attending and presenting at the upcoming American Academy of Neurology (AAN) 2025 Annual Meeting, which is being held in San Diego from April 5 – 9.
Read More
NeuroPace to Present at the 24th Annual Needham Virtual Healthcare Conference
Published: March 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
MOUNTAIN VIEW, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 24th Annual Needham Virtual Healthcare Conference at 3:00pm ET (12:00pm PT) on Tuesday, April 8, 2025.
Read More
NeuroPace, Inc. (NPCE) Q4 2024 Earnings Call Transcript
Published: March 04, 2025 by: Seeking Alpha
Sentiment: Neutral
NeuroPace, Inc. (NASDAQ:NPCE ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Jeremy Feffer - Investor Relations Joel Becker - Chief Executive Officer and Board Member Rebecca Kuhn - Chief Financial Officer, Vice President, Finance and Administration Conference Call Participants Priya Sachdeva - UBS Rohin Patel - JP Morgan Frank Takkinen - Lake Street Capital Markets Mike Kratky - Leerink Partners Vik Chopra - Wells Fargo Matthew Park - Cantor Fitzgerald Michael Pollard - Wolfe Research Operator Greetings and welcome to NeuroPace Fourth Quarter 2024 Earnings Call. At this time, all participants are in a …
Read More
NeuroPace (NPCE) Surges 5.8%: Is This an Indication of Further Gains?
Published: February 21, 2025 by: Zacks Investment Research
Sentiment: Positive
NeuroPace (NPCE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Read More
NeuroPace Announces Pricing of Public Offering of $65 Million of Common Stock
Published: February 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
MOUNTAIN VIEW, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE) today announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $10.00 per share.
Read More
NeuroPace Announces Proposed Public Offering of $65 Million of Common Stock
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
MOUNTAIN VIEW, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE) today announced that it intends to offer and sell, in an underwritten public offering, $65 million of shares of its common stock. All of the shares are being offered by NeuroPace. In addition, NeuroPace intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, …
Read More
About NeuroPace, Inc. (NPCE)
- IPO Date 2021-04-22
- Website https://www.neuropace.com
- Industry Medical - Devices
- CEO Mr. Joel D. Becker
- Employees 184